In 2011 Memorial Sloan Kettering continued to deliver the highest-quality patient care, make major contributions to cancer research and discovery, and lay the groundwork for significant progress in the years ahead.
Work led by Memorial Sloan Kettering scientists and physicians resulted in several significant treatment advances — in particular for metastatic melanoma and prostate cancer. Three new targeted therapies, all of which were developed by Memorial Sloan Kettering investigators, received approval from the US Food and Drug Administration, and are changing the standard of care for these diseases.
Basic science advances in 2011 were wide-ranging. Among many accomplishments, Memorial Sloan Kettering researchers pioneered insights into stem cell biology and its implications for translational medicine; provided a deeper understanding of how DNA integrity is maintained during cell division and reproduction; and made a breakthrough toward developing a computer method to predict a protein’s shape from its genetic sequence that could speed research in cancer and other diseases.
You can learn more about these developments, and others, in the 2011 Memorial Sloan Kettering Annual Report.